Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES

Clin Infect Dis. 2020 Jul 27;71(3):664-666. doi: 10.1093/cid/ciz1097.

Abstract

For persons with baseline Fibrosis-4 1.46-3.25, cirrhosis incidence/1000 patient-years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV monoinfected (P = .03). Cirrhosis risk was numerically higher but statistically nonsignificant among HBV/HCV coinfected (hazards ratio [HR] 1.51; 95% confidence intervals [CI], .37-6.05) but lower among those who attained sustained virologic response (HR, .52; 95% CI, .42-.63).

Keywords: ERCHIVES; HBV; HCV; HCV/HBV coinfection; fibrosis progression.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antiviral Agents / therapeutic use
  • Coinfection* / drug therapy
  • HIV Infections* / drug therapy
  • Hepacivirus
  • Hepatitis B* / complications
  • Hepatitis B* / drug therapy
  • Hepatitis C* / complications
  • Hepatitis C* / drug therapy
  • Hepatitis C, Chronic* / drug therapy
  • Humans
  • Liver Cirrhosis / drug therapy

Substances

  • Antiviral Agents